142 related articles for article (PubMed ID: 38295234)
1. Reply to Letter to the Editor: 'Cardiotoxicity Associated with Antihuman Epidermal Growth Factor Receptor-2 Therapy: Particular Aspects of a Specific Phenomenon'.
Şener YZ; Ardalı Düzgün S; Hazırolan T; Tokgözoğlu L
Anatol J Cardiol; 2024 Feb; 28(2):130-131. PubMed ID: 38295234
[No Abstract] [Full Text] [Related]
2. Cardiotoxicity Associated with Antihuman Epidermal Growth Factor Receptor-2 Therapy: Particular Aspects of a Specific Phenomenon.
Yalta K
Anatol J Cardiol; 2024 Feb; 28(2):128-129. PubMed ID: 38295233
[No Abstract] [Full Text] [Related]
3. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
[TBL] [Abstract][Full Text] [Related]
4. Reply to the Letter to the Editor: Is There a Cardiotoxicity Associated With Metallic Head Hip Prostheses? A Cohort Study in the French National Health Insurance Databases.
Lassalle M; Colas S; Zureik M; Dray-Spira R
Clin Orthop Relat Res; 2018 Dec; 476(12):2462-2463. PubMed ID: 30427317
[No Abstract] [Full Text] [Related]
5. EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation:
Alhoshani A; Alanazi FE; Alotaibi MR; Attwa MW; Kadi AA; Aldhfyan A; Akhtar S; Hourani S; Agouni A; Zeidan A; Korashy HM
Chem Res Toxicol; 2020 Jul; 33(7):1719-1728. PubMed ID: 32370496
[TBL] [Abstract][Full Text] [Related]
6. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
7. Reply to the letter to the editor 'Anti-EGFR therapy in oesophagogastric cancer: precise but not enough' by M. Salati and S. Cascinu.
Ruhstaller T; Langer R; Thuss-Patience P; Eisterer W; Stahl M
Ann Oncol; 2018 Sep; 29(9):2018. PubMed ID: 29992287
[No Abstract] [Full Text] [Related]
8. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
Florido R; Smith KL; Cuomo KK; Russell SD
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
[No Abstract] [Full Text] [Related]
9. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.
Hervent AS; De Keulenaer GW
Int J Mol Sci; 2012 Sep; 13(10):12268-86. PubMed ID: 23202898
[TBL] [Abstract][Full Text] [Related]
10. Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'. Reply.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Eur J Heart Fail; 2022 Aug; 24(8):1450-1451. PubMed ID: 35798652
[No Abstract] [Full Text] [Related]
11. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.
Bardaro F; Stirpe E
J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771
[TBL] [Abstract][Full Text] [Related]
13. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.
Mellon K; Thompson S; Charlton RG; Marsh C; Robinson M; Lane DP; Harris AL; Horne CH; Neal DE
J Urol; 1992 Feb; 147(2):496-9. PubMed ID: 1370701
[TBL] [Abstract][Full Text] [Related]
14. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem G; Lancellotti P; Kim SB
Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Magnetic Resonance Imaging Findings in Human Epidermal Growth Factor Receptor 2-Targeted Therapy-Related Cardiotoxicity.
Şener YZ; Ardalı Düzgün S; Hazırolan T; Tokgözoğlu L
Anatol J Cardiol; 2023 Dec; 27(12):E38-E39. PubMed ID: 38031670
[No Abstract] [Full Text] [Related]
16. Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Earl HM; Hiller L; Plummer C; Miles D; Wardley AM; Cameron DA; Dunn JA
Lancet; 2020 Feb; 395(10223):492-493. PubMed ID: 32061290
[No Abstract] [Full Text] [Related]
17. In Reply to the Letter to the Editor Titled "Which Epidemiological Factors Have the Most Influence on the EGFR Mutation Frequency in Lung Adenocarcinoma?".
Leduc N; Sabourin JC; Molinié V
J Thorac Oncol; 2016 Sep; 11(9):e114-5. PubMed ID: 27565406
[No Abstract] [Full Text] [Related]
18. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures.
Dias A; Claudino W; Sinha R; Perez CA; Jain D
Crit Rev Oncol Hematol; 2016 Aug; 104():42-51. PubMed ID: 27338847
[TBL] [Abstract][Full Text] [Related]
20. Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
Beau-Faller M; Cadranel J
Ann Oncol; 2016 Feb; 27(2):359-60. PubMed ID: 26658890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
